GlenMark Pharma - Sr Manager/Manager - Finance

Job Description:

- To handle the Business Finance Function for the API SBU by Managing complete financial business aspect in accordance with organisational requirement, policies & procedures.

- Prepare & review the monthly MIS for the API business SBU. Monthly MIS on SBU Performance w.r.t. Sales, GC, Receivables & FG Inventory, Various reports

- Prepare Annual budgets for API business w.r.t. Sales, GC, Receivables, Collections, DSO's, Inventory etc

- Prepare analysis of Accounts Receivables, Collections - Accounts Receivables (A/R) Management, Associated Banking operations for receivables & Conflict management (Legal & Insurance for overdue receivables) Receivables Management (Including Collections Management & Credit rating)

- FG Inventory - Monitoring & controlling monthly FG Inventory.

- Providing info to SBU head w.r.t. saleable inventory, ageing analysis of the same to take decisions for moving or writing off the same.

- Releasing Pricing Policy & controlling minimum selling prices (MSP) to ensure that SBU targeted GC % get achieved on external sales.

- Scrutiny of Expense GL's of SBU & Receivables Scrutiny of Expense GL's of SBU & Receivables

- Budget Monitoring / controlling and releasing budgets for cost centers at quarter ends.

- Product costing related support to SBU w.r.t. selling prices & GC on the products.

- Liasioning & attending MIS related queries of Corporate budgetary control.

Desired Candidate:

- CA / ICWA / MBA (Finance)

- 5-7 years of experience of business finance with pharma industry

- Mumbai based candidates only

- Working knowledge of SAP would be an added advantage

About Organisation:

Glenmark Pharmaceuticals Limited [Glenmark] is an India-based growing pharmaceutical company headquartered at Mumbai [formerly, Bombay]. Incorporated in 1977, the Company is focused on the manufacture and marketing of formulation products and active pharmaceutical ingredients [API] in India as well as globally and enjoys a diversified and growing presence in regulated and developing international markets. Over the past five years, the Company has also catalyzed its growth through investment in dedicated research and development including cutting-edge New Chemical Entity [NCE] research.